Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non Operating Income: 2020-2025

Historic Other Non Operating Income for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $37,000.

  • Apellis Pharmaceuticals' Other Non Operating Income fell 47.14% to $37,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 839.25%. This contributed to the annual value of -$2.2 million for FY2024, which is 198.49% down from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Other Non Operating Income stood at $37,000 for Q3 2025, which was down 74.66% from $146,000 recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Other Non Operating Income high stood at $219,000 for Q4 2023, and its period low was -$55.2 million during Q4 2021.
  • Its 3-year average for Other Non Operating Income is -$261,455, with a median of -$63,000 in 2023.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Other Non Operating Income plummeted by 905.94% in 2024, and later spiked by 508.33% in 2025.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Other Non Operating Income stood at -$55.2 million in 2021, then spiked by 99.55% to -$246,000 in 2022, then surged by 189.02% to $219,000 in 2023, then tumbled by 905.94% to -$1.8 million in 2024, then slumped by 47.14% to $37,000 in 2025.
  • Its Other Non Operating Income was $37,000 in Q3 2025, compared to $146,000 in Q2 2025 and -$165,000 in Q1 2025.